Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Naya Biosciences Inc (NAYA)

Naya Biosciences Inc (NAYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF” GlobeNewswire - Thu Apr 24, 2025

NAYA : 2.20 (+8.37%)
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.” GlobeNewswire - Mon Apr 14, 2025

NAYA : 2.20 (+8.37%)
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025 GlobeNewswire - Thu Mar 13, 2025

NAYA : 2.20 (+8.37%)
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment GlobeNewswire - Tue Feb 25, 2025

NAYA : 2.20 (+8.37%)
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering  GlobeNewswire - Mon Jan 13, 2025

NAYA : 2.20 (+8.37%)
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody GlobeNewswire - Mon Jan 6, 2025

NAYA : 2.20 (+8.37%)
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire - Thu Oct 31, 2024

NAYA : 2.20 (+8.37%)
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma GlobeNewswire - Thu Oct 24, 2024

INVO : 0.8330 (-2.91%)
NAYA : 2.20 (+8.37%)
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences GlobeNewswire - Mon Oct 21, 2024

INVO : 0.8330 (-2.91%)
NAYA : 2.20 (+8.37%)

Barchart Exclusives

1 Ultimate Picks-and-Shovels AI Stock That Has a Billionaire Investor Loading Up Barchart - 34 minutes ago
Elliott Management just made a power move that has the market buzzing, taking an undisclosed stake in London Stock Exchange Group. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot